Publications and related articles about us and the wound care industry

Peer-reviewed NAZARÉ Trial Protocol Published in Trials

Multicenter randomized controlled trial evaluates COMS® therapy as an adjunct to standard care for vascular ulcers across five European countries.

Read more
Peer-reviewed NAZARÉ Trial Protocol Published in Trials
European KOLs Initiate NAZARÉ Post-Market Clinical Study

European wound care key opinion leaders initiate NAZARÉ, an investigator-initiated post-market study evaluating COMS® therapy across Europe.

Read more
European KOLs Initiate NAZARÉ Post-Market Clinical Study
FDA Breakthrough Device Designation for COMS® One Therapy System

Piomic Medical Receives FDA Breakthrough Device Designation for its novel COMS® One Therapy System.

Read more
FDA Breakthrough Device Designation for COMS® One Therapy System
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts

MAVERICKS study sets new standards in the wound-care industry amid major reimbursement changes.

Read more
MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts
Piomic Medical Secures Eurostars Financing for COMS® Blue

Piomic Medical secures Eurostars funding for COMS® Blue, advancing antibiotic-independent wound infection treatment with real-time diagnostics and digital health.

Read more
Piomic Medical Secures Eurostars Financing for COMS® Blue
Piomic Medical Wins EPUAP 2024 Most Innovative Product Award

Award highlights promising potential of COMS® therapy for severe pressure ulcers, with off-label data showing “clinically significant rates of wound area reduction and wound closure“1.

Read more
Piomic Medical Wins EPUAP 2024 Most Innovative Product Award
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care

New Study highlights COMS® as a promising tool for debridement and wound bed preparation for other therapies, such as skin grafts.

Read more
New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites

Trial seeks to assure Piomic’s COMS® treatment is safe and effective in therapy-refractory diabetic foot ulcers

Read more
Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites
Piomic receives Medicare Category B Designation for MAVERICKS clinical trial

CMS has approved the COMS One device for Category B designation and for Medicare coverage purposes during Piomic's IDE study

Read more
Piomic receives Medicare Category B Designation for MAVERICKS clinical trial
Piomic receives certification under MDR, the new European Medical Device Regulation

Piomic Medical has received certificates according to MDR for its Class IIa and Class Is medical devices of the COMS® One Therapy System.

Read more
Piomic receives certification under MDR, the new European Medical Device Regulation
Bernard Laurel appointed as the President of Piomic Medical Inc.

M&A experienced advanced wound care leader appointed as President of US Subsidiary Piomic Medical Inc.

Read more
Bernard Laurel appointed as the President of Piomic Medical Inc.
Piomic Medical receives unconditional FDA IDE approval for U.S. pivotal trial

Piomic Medical receives unconditional IDE approval from the FDA for MAVERICKS, the pivotal study for the COMS® One Therapy System in patients with refractory diabetic foot ulcers.

Read more
Piomic Medical receives unconditional FDA IDE approval for U.S. pivotal trial
Bertrand Hughes appointed as the Chairman of the Board of Directors

Highly experienced expert in advanced wound care appointed Chairman of the Board of Directors.

Read more
Bertrand Hughes appointed as the Chairman of the Board of Directors
Piomic Medical closes oversubscribed financing round to bring COMS® therapy into US patients’ homes

Piomic Medical closes oversubscribed financing round to bring COMS® therapy into US patients’ homes

Read more
Piomic Medical closes oversubscribed financing round to bring COMS® therapy into US patients’ homes
Piomic selected as Ground-Breaking Swiss Startup Innovation

Piomic selected as groundbreaking Swiss start-up innovation

Read more
Piomic selected as Ground-Breaking Swiss Startup Innovation
Karina Candrian joins the Board of Directors

As a serial MedTech entrepreneur, Karina Candrian has more than 20 years of practical experience in the healthcare industry and covers various functions along the entire value chain.

Read more
Karina Candrian joins the Board of Directors
Publication of COMS01 clinical trial results in the Journal of Wound Care

In a multicentre clinical trial COMS® therapy significantly reduced the time to wound closure for hard-to-heal wounds when compared with Standard of Care (SOC) alone

Read more
Publication of COMS01 clinical trial results in the Journal of Wound Care
Piomic receives the Seal of Excellence from the European Commission

Piomic receives the Seal of Excellence from the European Commission

Read more
Piomic receives the Seal of Excellence from the European Commission
Piomic Medical AG has been awarded with the Innosuisse Label.

Piomic Medical AG has been awarded with the prestigious Innosuisse Label.

Read more
Piomic Medical AG has been awarded with the Innosuisse Label.
Piomic signs Cooperation Agreement with the Geblog AG

We are proud to announce that we have signed a cooperation agreement with the Geblog AG.

Read more
Piomic signs Cooperation Agreement with the Geblog AG
9th Balgrist Symposium on Diabetic Foot

Dr. Martin Berli featured COMS® technology during his talk about new advanced treatment methods of diabetic foot ulcers.

Read more
9th Balgrist Symposium on Diabetic Foot
20th SAfW Symposium – Advantages of COMS® technology

Dr. Jürg Traber and Maria Signer from Venenklinik Bellevue shared their experience about the advantages of COMS® Therapy at the 20th SAfW Symposium.

Read more
20th SAfW Symposium – Advantages of COMS® technology
Piomic is supported by the SME instrument

Piomic was chosen for the SME instrument and funded under grant agreement No. 886276 from the European Union’s Horizon 2020 research and innovation programme.

Read more
Piomic is supported by the SME instrument
Guest Speaker @EWMA 2019

Chief scientific officer Marc Augsburger joining a #EWMAMasterclass to elaborate on the role of molecular oxygen in wound healing.

Read more
Guest Speaker @EWMA 2019
Winner W.A. De Vigier Startup Award 2019

Piomic is very proud to be among the winners of the W.A. De Vigier Startup Award 2019.

Read more
Winner W.A. De Vigier Startup Award 2019
W. A. de Vigier award Top 60

Piomic has been selected to pitch at the W.A. de Vigier 2019 startup competition

Read more
W. A. de Vigier award Top 60
Seed Financing

Piomic Closes Seed Round

Read more
Seed Financing
Swiss MedTech Expo

Piomic visits Swiss MedTech Expo in Luzern.

Read more
Swiss MedTech Expo
Swiss MedTech Day

Piomic visits Swiss MedTech Day in Bern.

Read more
Swiss MedTech Day
Kickstart Accelerator 2016

Swiss president visits Piomic during the Kickstart Accelerator.

Read more
Kickstart Accelerator 2016
CTI Coaching Acceptance

Piomic gets accepted for the CTI Phase III Coaching program.

Read more
CTI Coaching Acceptance
Incorporation of Piomic

Piomic Medical gets incorporated as Aktiengesellschaft in Zurich.

Read more
Incorporation of Piomic
Don't miss our updates!
You must complete your email.
You must accept our Privacy Policy